___

• Kaynaklar 1.Schwarz HP, Haberman BE, Ruddy RM. Hyperbilirubinemia.Current guidelines and emerging therapies. Pediatr Emer Care2011; 27: 884- 89. 2.Hansen TWH, Bratlid D. Physiology of neonatal unconjuga-ted hyperbilirubinemia. In: Stevenson DK, Maisels MJ,Watchko JF, eds. Care of Jaundiced Neonate. New York:McGraw-Hill, 2012: 65-95. 3.Kaplan M, Wong RJ, Sibley E, Stevenson DK. Neonatal jaun-dice and liver disease. In: Neonatal-Perinatal Medicine: Di-seases of the Fetus and Infant, 9th ed, Martin RJ, Fanaroff AA,Walsh MC (Eds), Elsevier Mosby, St. Louis 2011. Vol 2, p.1443. 4.Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balancedpolymorphism for regulation of bilirubin metabolism? ProcNatl Acad Sci USA 1998 7;95:8170-4. 5.Slusher TM, Vreman HJ, McLaren DW, Lewison LJ, BrownAK, Stevenson DK. Glucose-6-phosphate dehydrogenase de-ficiency and carboxyhemoglobin concentrations associated withbilirubin-related morbidity and death in Nigerian infants. JPediatr 1995;126:102-8. 6.Kaplan M, Hammerman C, Vreman HJ, Wong RJ, StevensonDK. Direct antiglobulin titer strength and hyperbilirubinemia.Pediatrics 2014;134:e1340-4. 7.Stevenson DK, Ostrander CR, Hopper AO, Cohen RS, John-son JD. Pulmonary excretion of carbon monoxide as an in-dex of bilirubin production. IIa. Evidence for possible dela-yed clearance of bilirubin in infants of diabetic mothers. J Pe-diatr 1981;98:822-4. 8.Grunebaum E, Amir J, Merlob P, Mimouni M, Varsano I. Bre-ast mild jaundice: natural history, familial incidence and lateneurodevelopmental outcome of the infant. Eur J Pediatr1991;150:267-70. 9.American Academy of Pediatrics, Clinical Practice Guideli-ne, Subcommittee on Hyperbilirubinemia. Management of thenewborn 35 or more weeks of gestation. Pediatrics 2004; 114:297-316. 10.Kaplan M, Muraca M, Hammerman C, et al. Inbalance bet-ween production and conjugation of bilirubin: a fundamen-tal concept in the mechanism of neonatal jaundice. Pediatrics2002; 110: e47. 4. 11.Davidson L, Thilo EH. How to make kernicterus a “neverevent”. Neoreviews 2003; 4:e308-14. 12.Manning D, Todd P, Maxwell M, Jane Platt M. Prospectivesurveillance study of severe hyperbilirubinaemia in the new-born in the UK and Ireland. Arch Dis Child Fetal NeonatalEd 2007; 92: F342–46. 13.Kaplan M, Merlob P, Regev R. Israel guidelines for the ma-nagement of neonatal hyperbilirubinemia and prevention ofkernicterus. J Perinatol 2008; 28: 389-97. 14.Çoban A, Türkmen M, Gürsoy T. Yenidoğan sarılıklarında yak-laşım, izlem ve tedavi rehberi 2014. www. neonatology.org.tr/wp-content/ uploads/ 2016/ 12/ sarilik. pdf 15.Volpe JJ. Neurology of the Newborn, 4th ed, WB Saunders,Philadelphia 2001 16.Sgro M, Campbell D, Barozzino T, Shah V. Acute neurologi-cal findings in a national cohort of neonates with severe neo-natal hyperbilirubinemia. J Perinatol 2011; 31:392. 17.Croen LA, Yoshida CK, Odouli R, Newman TB.Neonatal hyper-bilirubinemia and risk of autism spectrum disorders. Pediat-rics 2005;115:e135-8. 18.Maimburg RD, Bech BH, Vaeth M, Møller-Madsen B, OlsenJ.Neonatal jaundice, autism, and other disorders of psycho-logical development. Pediatrics 2010;126:872-8. 19.Riskin A, Tamir A, Kugelman A, Hemo M, Bader D. Is visu-al assessment of jaundice reliable as a screening tool to de-tect significant neonatal hyperbilirubinemia? J Pediatr2008;152:782-7, 787.e1-2. 20.Bhutani VK, Johnson L, Sivieri EM. Predictive ability of a pre-discharge hour-specific serum bilirubin for subsequent sig-nificant hyperbilirubinemia in healthy term and near-term new-borns. Pediatrics 1999;103:6-14. 21.Dennery PA, Seidman DS, Stevenson DK.Neonatal hyperbi-lirubinemia. N Engl J Med 2001;344:581-90. 22.Maisels MJ.What's in a name? Physiologic and pathologicjaundice: the conundrum of defining normal bilirubin levelsin the newborn. Pediatrics 2006;118:805-7. 23.Maisels MJ, Bhutani VK, Bogen D, Newman TB, Stark AR,Watchko JF.Hyperbilirubinemia in the newborn infant > or=35 weeks' gestation: an update with clarifications. Pediat-rics 2009;124:1193-8. 24.Maisels MJ. Use TcB as a screening tool for jaundiced new-borns. AAP News 2004;25:9. 25.Taylor JA, Burgos AE, Flaherman V, Chung EK, Simpson EA,Goyal NK, Von Kohorn I, Dhepyasuwan N; BORN Investiga-tors.Utility of Decision Rules for transcutaneous Bilirubin Mea-surements.Pediatrics 2016;137. pii: e20153032. 26.Grohmann K, Roser M, Rolinski B, Kadow I, Müller C, Go-erlach-Graw A, Nauck M, Küster H. Bilirubin measurementfor neonates: comparison of 9 frequently used methods. Pe-diatrics 2006;117:1174-83. 27.Olusanya B, Imosemi DO, Emokpae AA. Differences Betwe-en Transcutaneous and Serum Bilirubin Measurements in BlackAfrican Neonates. Pediatrics 2016;138. pii: e20160907. 28.Grabenhenrich J, Grabenhenrich L, Bührer C, Berns M. Trans-cutaneous bilirubin after phototherapy in term and preterminfants. Pediatrics 2014;134:e1324-9. 29.Bhutani VK, Srinivas S, Castillo Cuadrado ME, Aby JL, WongRJ, Stevenson DK. Identification of neonatal haemolysis: anapproach to predischarge management of neonatal hyperbi-lirubinemia. Acta Paediatr 2016;105:e189-94. 30.Ahlfors CE, Wennberg RP, Ostrow JD, Tiribelli C. Unbound(free) bilirubin: improving the paradigm for evaluating neo-natal jaundice. Clin Chem 2009;55:1288-99. 31.McLin VA, Balistereri WF. Approach to neoonatal cholesta-sis. In: Pediatric Gastrointestinal Disease: Pathopsychology,Diagnosis, Management, 4th, Walker WA, Goulet O, Klein-man RE, et al (Eds), BC Decker, Ontario 2004. p.1079. 32.Fawaz R, Baumann U, Ekong U, Fischler B, Hadzic N, MackCL, McLin VA, Molleston JP, Neimark E, Ng VL, Karpen SJ.Guideline for the Evaluation of Cholestatic Jaundice in Infants:Joint Recommendations of the North American Society for Pe-diatric Gastroenterology,Hepatology, and Nutrition and theEuropean Society for PediatricGastroenterology, Hepatology,and Nutrition.J Pediatr Gastroenterol Nutr 2017;64:154-68. 33.Maisels MJ, Kring E. Rebound in serum bilirubin level follo-wing intensive phototherapy. Arch Pediatr Adolesc Med2002;156:669-72. 34.Tan KL. Comparison of the efficacy of fiberoptic and conven-tional phototherapy for neonatal hyperbilirubinemia. J Pedi-atr 1994;125:607-12. 35.Bhutani VK; Committee on Fetus and Newborn; American Aca-demy of Pediatrics. Phototherapy to prevent severe neonatalhyperbilirubinemia in the newborn infant 35 or more weeksof gestation. Pediatrics 2011;128:e1046-1052. 36.Atkinson M, Budge H. Review of the NICE guidance on neo-natal jaundice. Arch Dis Child Educ Pract Ed 2011;96:136–40. 37.Eggert P, Stick C, Schröder H.On the distribution of irradia-tion intensity in phototherapy. Measurements of effective ir-radiance in an incubator. Eur J Pediatr 1984;142:58-61. 38.NM, Ahmad Kamar A, Choo YM, Kong JY, Ngim CF. Fluidsupplementation for neonatal unconjugated hyperbilirubinae-mia.Cochrane Database Syst Rev 2017;8:CD011891. 39.Chang PW, Kuzniewicz MW, McCulloch CE, Newman TB. AClinical Prediction Rule for Rebound Hyperbilirubinemia Fol-lowing Inpatient Phototherapy. Pediatrics 2017;139. pii:e20162896. 40.McDonagh AF.Bilirubin, copper-porphyrins, and the bronze-baby syndrome. J Pediatr 2011;158:160-4. 41.Lightner DA, Linnane WP, Ahlfors CE. Bilirubin photooxida-tion products in the urine of jaundiced neonates receiving pho-totherapy. Pediatr Res 1984; 18: 696–700. 99. 42.Sisson TR. Photodegradation of riboflavin in neonates. FedProc 1987; 46: 1883–85. 43.Hooman N, Honarpisheh A. The effect of phototherapy on uri-nary calcium excretion in newborns. Pediatr Nephrol 2005;20: 1363–64. 44.Chen A, Du L, Xu Y et al. The effect of blue light exposure onthe expression of circadian genes: bmal1 and cryptochrome1 in peripheral blood mononuclear cells of jaundiced neona-tes. Pediatr Res 2005; 58:1180–84. 45.MacDonald MG, Ramasethu J. Atlas of procedures in neona-tology. Philadelphia: Lippincott Williams & Wilkins, a Wol-ters Kluwer Business, 2007. 46.Yaffe SJ, Dorn LD. Effects of prenatal treatment with pheno-barbital. Dev Pharmacol Ther 1990;15:215-23. 47.Wong RJ, Bhutani VK, Vreman HJ, Stevenson DK. Tin meso-porphyrin for the prevention of severe neonatal hyperbiliru-binemia. NeoReviews 2007;8:e77. 48.Heady JA, Morris JN, Oliver MF. WHO clofibrate/choleste-rol trial: clarifications. Lancet 1992;340(8832):1405-6. 49.Honar N, Ghashghaei Saadi E, Saki F, Pishva N, ShakibazadN, Hosseini Teshnizi S.Effect of Ursodeoxycholic Acid on In-direct Hyperbilirubinemia in Neonates Treated With Photot-herapy.J Pediatr Gastroenterol Nutr 2016;62:97-100. 50.Kaplan M, Hammerman C. Hemolytic disorders and their ma-nagement. In: Stevenson DK, Maisels MJ, Watchko JF, eds.Care of Jaundiced Neonate. New York: McGraw-Hill, 2012.